United States News Todas as matérias

Business First Bancshares (NASDAQ:BFST), the parent company of b1BANK, reported its first-quarter 2026 financial results on Monday, highlighting a period of significant expansion following its recent merger activity.

Bank of Marin Bancorp (NASDAQ:BMRC) reported a strong return to profitability for the first quarter of 2026 on Monday, posting net income of $8.5 million.

Johnson & Johnson (NYSE:JNJ) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY (nipocalimab-aahu).

AbbVie (NYSE:ABBV) announced on Monday, April 27, 2026, that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for SKYRIZI (risankizumab-rzaa).

Norwood Financial (NASDAQ:NWFL), the parent company of Wayne Bank, announced its financial results for the first quarter of 2026 on Monday, a period defined by the successful closing and integration of Presence Bancshares.

Thermo Fisher Scientific (NYSE:TMO) announced on Monday that it has entered into a definitive agreement to sell its microbiology business to Astorg, a prominent pan-European private equity firm.

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its supplemental Biologics License Application (sBLA) for Ziihera (zanidatamab-hrii).

CorMedix (NASDAQ:CRMD) announced positive topline results on Monday from the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for the prevention of invasive fungal diseases in adult allogeneic hematopoietic stem cell transplant (HSCT) patients.

Alterity Therapeutics (NASDAQ:ATHE) announced on Monday that it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a second Type C meeting regarding its ATH434 Phase 3 program.

Intellia Therapeutics (NASDAQ:NTLA) today announced positive topline results from its pivotal Phase 3 HAELO clinical trial evaluating lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR-based gene editing therapy for patients with hereditary angioedema (HAE).

Purple Biotech (NASDAQ:PPBT) released promising preclinical data on Monday for its lead therapeutic candidate, IM1240, demonstrating consistent anti-tumor activity across seven distinct patient-derived tumor samples.

HBT Financial (NASDAQ:HBT) reported its first-quarter 2026 financial results on Monday, highlighting a transformative period following the completion of its acquisition of CNB Bank shares.

Lakeland Financial (NASDAQ:LKFN), the parent company of Lake City Bank, reported record-breaking financial results for the first quarter of 2026 on Monday.

Alliance Resource Partners (NASDAQ:ARLP) reported its financial and operating results for the first quarter of 2026 on Monday, characterized by record-breaking performance in its royalty segments despite pricing challenges in the coal market.

SCHMID Group (NASDAQ:SHMD) released its first-quarter operational metrics for 2026 on Monday, reporting total revenues of €18.2 million.

Granite (NYSE:GVA) announced on Monday the completion of its acquisition of Kenny Seng Construction, a strategic move aimed at solidifying the company's vertically integrated construction and materials platform in Utah.

Eli Lilly (NYSE:LLY) has reached a definitive agreement to acquire Ajax Therapeutics, a biotechnology firm specializing in next-generation therapies for myeloproliferative neoplasms (MPNs).

The U.S. Food and Drug Administration has approved AstraZeneca’s (NASDAQ:AZN) Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector, the Saphnelo Pen.

Vertiv Holdings (NYSE:VRT) announced the acquisition of Strategic Thermal Labs (STL) on Monday, a move designed to deepen its engineering expertise in liquid cooling for high-density computing environments.

Easterly Government Properties (NYSE:DEA) reported its financial results for the first quarter of 2026 on Monday, highlighting a period of strategic acquisition and capital activity.

Adagio Medical Holdings (NASDAQ:ADGM) unveiled positive six-month results from its FULCRUM-VT clinical trial on Monday, providing the foundational data required for its forthcoming Food and Drug Administration (FDA) Premarket Approval application.

Domino’s Pizza (NASDAQ:DPZ) reported its first-quarter 2026 financial results on Monday, revealing a resilient bottom line supported by robust international expansion despite softening demand in several overseas markets.

Relay Therapeutics (NASDAQ:RLAY) announced on Monday that it will advance its lead candidate, zovegalisib, into a planned Phase 3 frontline trial for the treatment of PIK3CA-mutated, HR+/HER2- metastatic breast cancer.

Semiconductor manufacturer onsemi (NASDAQ:ON) and Chinese electric vehicle maker NIO (NYSE:NIO) have expanded their strategic collaboration to accelerate the adoption of next-generation 900-volt electric vehicle architectures.